Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
— Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share — — Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies — — Nestlé Health Science CEO Greg Behar
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights
Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
Toggle Summary Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting
— Oral Presentation on Data from Aimmune’s Pivotal Phase 3 PALISADE Trial — — Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
Toggle Summary Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann , M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors,
Toggle Summary Aimmune Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018
Toggle Summary Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
— Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101 — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the
Toggle Summary Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 26, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas , M.D., will participate in a fireside chat at the Cantor Global
Toggle Summary Aimmune Therapeutics to Present at Three Investor Conferences in September
Wells Fargo Healthcare Conference , September 5 Baird Global Healthcare Conference , September 6 Bank of America Merrill Lynch Global Healthcare Conference , September 12 BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 29, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2018 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018 .
Toggle Summary Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., will give his first public presentation as the company’s President and CEO